Back to search

National and Kapodistrian University of Athens

Ανοσοθεραπεία Her2/neu όγκων με ανασυνδυασμένα βιομόρια

Abstract

dc:description

The family of Epidermal Growth Factor Receptors (ErbB-Her family) belongs to tyrosinic kinase receptors. It consists of 4 transmembrane receptors: EGFR (ErbB1/Her1), Her2 (ErbB2), Her3 (ErbB3) and Her4 (ErbB4). These receptors are located in cells of epithelial origin, where their base-lateral placement allows them to intervene in the transfer of signals between mesenghyma and epithelium. These signals control cell fate by activating and regulating a total of cellular answers, like proliferation, immigration, adherence, differentiation and apoptosis. The ErbB receptor family along with their ligands and the proteins that intracellularly transport the signal comprise a highly sophisticated and dynamic signaling network. 13 ligands are bound in the extracellular domain of these receptors, activating them by forming dimmers. At the intracellular domain of these receptors a large number of signaling molecules together with adaptor proteins are connected, activating various signaling pathways like the MAP kinase path, the PI3 kinase path, the Cγ phospholipase path, STAT factors, cyclins and factors of cell cycle regulation and cell adhesion and polarity molecules. These pathways participate in the intracellular transfer of signals and activate specific transcription factors including fos, jun and myc factors, members of the Ets protein family like the GABP and members of a zing protein family including Sp1 and Egr1. The final outcome of the ErbB signaling network depends on the ligand bound to the receptor and the type of dimmer formed. Any alteration of the highly firmed network leads to abnormalities and carcinogenesis. The second member of the ErbB receptor family, ErbB2, is known as the “orphan” receptor, as it is deprived of ligands. The structure of ErbB2 receptor includes an extracellular domain of 620 a.a., a transmembrane domain of 23 a.a. and an intracellular domain of 580 a.a. where its catalytic activity is located. It has a unique conformation that corresponds to the ligand-bound active conformation of the rest ErbB receptors. This trait renders it the preferred receptor for forming heterodimers with the rest family members and especially with ErbB3. ErbB2/ErbB3 heterodimer has a highly mitogenic and oncogenic potential, as it promotes signaling through various pathways. These pathways lead to cell survival, anti-apoptotic signals and cell proliferation. In the physiologic epithelial cells ErbB2 receptor has a low-expression profile. However, in several cancers of epithelial origin like lung, salivary glands, kidney, bladder and ovary cancer, this receptor is overexpressed. The correlation between ErbB2 expression profile and cancer is better studied in breast cancers, where in 15-30% of invasive ductal carcinomas overexpress ErbB2 receptor because of gene amplification (up to 50 copies) or transcription deregulation. ErbB2 overexpresion is associated with increased tumor size, increased lymph metastasis, increased number of tumor cells in S phase, irregular number of chromosomes and decreased percentage of steroid hormones receptors. ...................

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Dimitriadis, Alexios
  • Δημητριάδης, Αλέξιος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/25405

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Dimitriadis, Alexios; Δημητριάδης, Αλέξιος. Ανοσοθεραπεία Her2/neu όγκων με ανασυνδυασμένα βιομόρια. National and Kapodistrian University of Athens, 2009. http://hdl.handle.net/10442/hedi/25405